These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3276544)

  • 21. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
    Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
    Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of lymphocyte subsets after autologous bone marrow transplantation with marrow treated by ASTA Z 7557 in acute leukemia: incidence of the in vitro treatment.
    Le Blanc G; Douay L; Laporte JP; Dominh A; Deloux J; Najman A; Duhamel G; Gorin NC
    Exp Hematol; 1986 Jun; 14(5):366-71. PubMed ID: 3519264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
    Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
    Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
    Miller G; Brashear T; Stone M; Fay J
    Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
    Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
    Douay L; Gorin NC; Mary JY; Duhamel G
    C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
    Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
    Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
    Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
    Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
    Chao NJ; Aihara M; Blume KG; Sikic BI
    Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
    de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
    Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows.
    Praloran V; Dobo I; Garand R; Klausman M; Naud MF; Milpied N; Harousseau JL
    Leukemia; 1990 Apr; 4(4):282-6. PubMed ID: 2366583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
    Genevay MC; Mormont C; Thomas F; Berthier R
    Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.